Recently, chemotherapy-free regimens combining blinatumomab with a BCR::ABL1 TKI have shown high rates of deep molecular responses and encouraging survival in Ph + ALL, even without routine alloSCT consoildation [2, 3]. Here, ABL1 is linked to acute lymphoblastic leukemia.